NOVA™ Now Available in Europe
Chicago, IL, October 02, 2008 --(PR.com)-- NOVA™, the most advanced technology to quantitatively and non-invasively measure blood flow using magnetic resonance imaging, will now be available to vascular patients in Europe. Developer and producer VasSol, Inc. this month announced their partnership with Italian distributor Tekmed Instruments.
Starting in October, Tekmed Instruments will offer NOVA™ (Non-invasive Optimal Vessel Analysis) software for licensing throughout Italy. Tekmed, headquartered in Milan, has served as an exclusive distributor in the medical sector for 30 years.
NOVA™ is already available throughout the United States.
About NOVA™
NOVA™, an innovative vessel flow analysis software, works with any high field MRI scanner. Unlike other imaging methods, NOVA Quantitative MRA, or QMRA, does not require injection of a contrast solution or expose the patient to radiation. Highly accurate and reliable, NOVA™ provides clinicians with the objective data necessary to recommend management.
NOVA™ is available for the cerebrovascular, renal and peripheral vascular applications.
About VasSol
VasSol, Inc., creators of the revolutionary NOVA™ technology, is a joint effort of vascular experts and leaders in advanced computer modeling. NOVA™ is the culmination of 11 years of research and clinical study conducted at the University of Illinois at Chicago.
Their mission is to provide physicians with vital information on blood flow to guide clinical decision-making and help ensure positive patient outcomes.
On the Web:
www.vassolinc.com
ww.tekmed.it
###
Starting in October, Tekmed Instruments will offer NOVA™ (Non-invasive Optimal Vessel Analysis) software for licensing throughout Italy. Tekmed, headquartered in Milan, has served as an exclusive distributor in the medical sector for 30 years.
NOVA™ is already available throughout the United States.
About NOVA™
NOVA™, an innovative vessel flow analysis software, works with any high field MRI scanner. Unlike other imaging methods, NOVA Quantitative MRA, or QMRA, does not require injection of a contrast solution or expose the patient to radiation. Highly accurate and reliable, NOVA™ provides clinicians with the objective data necessary to recommend management.
NOVA™ is available for the cerebrovascular, renal and peripheral vascular applications.
About VasSol
VasSol, Inc., creators of the revolutionary NOVA™ technology, is a joint effort of vascular experts and leaders in advanced computer modeling. NOVA™ is the culmination of 11 years of research and clinical study conducted at the University of Illinois at Chicago.
Their mission is to provide physicians with vital information on blood flow to guide clinical decision-making and help ensure positive patient outcomes.
On the Web:
www.vassolinc.com
ww.tekmed.it
###
Contact
VasSol Inc.
Kate Galbreath
312-601-4431
www.vassolinc.com
Contact
Kate Galbreath
312-601-4431
www.vassolinc.com
Categories